Results 261 to 270 of about 491,747 (317)

Esketamine/Ketamine: Dual‐Action Mechanisms and Clinical Prospects beyond Anesthesia in Psychiatry, Immunology, and Oncology

open access: yesAdvanced Science, Volume 13, Issue 7, 3 February 2026.
Esketamine and ketamine are widely used for perioperative analgesia and anesthesia. Despite their established roles in analgesia, sedation, and anesthesia, as well as emerging antidepressant, anti‐tumor, and anti‐inflammatory effects, their clinical use is limited due to side effects and addiction potential.
Yinxin Wang   +7 more
wiley   +1 more source

Crossing the Blood–Brain Barrier with Molecularly Imprinted Polymeric Nanocarriers: An Emerging Frontier in Brain Disease Therapy

open access: yesAdvanced Science, Volume 13, Issue 7, 3 February 2026.
Molecularly imprinted polymeric nanocarriers (nanoMIPs) offer robust, antibody‐mimetic platforms to overcome the blood‐brain barrier. The article surveys nanoMIP design and ligand‐directed surface engineering that harness receptor‐mediated transcytosis, and highlights therapeutic and diagnostic applications in neurodegeneration, brain tumors and ...
Ranjit De, Shuliang Shi, Kyong‐Tai Kim
wiley   +1 more source

AI‐Assisted Bioelectronics for Personalized Health Management

open access: yesAdvanced Electronic Materials, Volume 12, Issue 3, 4 February 2026.
Recent advances in artificial intelligence (AI)‐assisted bioelectronics, including materials, device fabrication, working mechanisms, AI‐hardware integration, and proof‐of‐concept applications in digital health management, are summarized. The emergence of AI‐assisted bioelectronic systems and potential solutions to existing challenges are discussed ...
Huiwen Xiong   +6 more
wiley   +1 more source

Reduced triacylglycerols and lipid droplets are associated with resilience to Alzheimer's disease

open access: yesAlzheimer's &Dementia, Volume 22, Issue 2, February 2026.
Abstract INTRODUCTION Although it has become clear that alterations in lipid metabolism are associated with Alzheimer's disease (AD), it is unclear how they contribute to both cognitive decline and the pathophysiology of AD. METHODS Lipidomics and activity‐based protein profiling (ABPP) were performed in the frontal cortex of control, AD and resilient ...
Daan van der Vliet   +12 more
wiley   +1 more source

Bispecific Antibodies Versus Chimeric Antigen Receptor T‐Cell Therapy in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma: A Comparative Narrative Review of Efficacy, Safety, and Accessibility

open access: yesCancer Medicine, Volume 15, Issue 2, February 2026.
ABSTRACT Introduction Diffuse large B‐cell lymphoma (DLBCL) is the most common subtype of non‐Hodgkin lymphoma, and despite advances in frontline therapies such as rituximab, cyclophosphamide, doxorubicin hydrochloride (hydroxydaunorubicin), vincristine sulfate (Oncovin), and prednisone, approximately 30%–40% of patients develop relapsed or refractory (
Dana Sofian Abou   +6 more
wiley   +1 more source

Importance of Smell Loss to Patients With Chronic Rhinosinusitis With Nasal Polyps: Options for Management and Recovery

open access: yesClinical and Translational Allergy, Volume 16, Issue 2, February 2026.
ABSTRACT Primary diffuse type 2‐dominant chronic rhinosinusitis with nasal polyps (CRSwNP) is an inflammatory disease of the nasal cavity and paranasal sinuses associated with significant morbidity. Impaired sense of smell is a cardinal symptom of CRSwNP and one of the most burdensome for patients, impacting quality of life, mental health, and even ...
Thomas S. Higgins   +9 more
wiley   +1 more source

Real‐World Effectiveness of Mepolizumab in Patients With Chronic Rhinosinusitis With Nasal Polyps: Findings From the European CRS Outcome Registry (CHRINOSOR)

open access: yesClinical and Translational Allergy, Volume 16, Issue 2, February 2026.
ABSTRACT Background The SYNAPSE phase 3 study demonstrated that mepolizumab significantly improves nasal polyp score (NPS), quality of life and symptom severity in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). Objective We aimed to evaluate mepolizumab effectiveness in a real‐world cohort from 12 tertiary centers in 6 European ...
Isam Alobid   +30 more
wiley   +1 more source

Microbial‐Immune Interplay in CNS Autoimmune Diseases: Lessons from Animal Models and Clinical Studies

open access: yesEuropean Journal of Immunology, Volume 56, Issue 2, February 2026.
Mechanism of action of the intestinal microbiota on CNS autoimmune diseases. Environmental factors shape gut microbiota composition; dysbiosis alters microbial metabolites and antigenic signals. These modulate innate and adaptive immunity, affect barrier integrity, and influence CNS‐resident cells such as microglia and astrocytes, contributing to ...
Matteo Ceccon, Francesca Ronchi
wiley   +1 more source

Home - About - Disclaimer - Privacy